Piramal Pharma has reported a profit of Rs 50 million for the second quarter of fiscal year 2027, surprising analysts who had expected a loss. This turnaround, driven by growth in its CDMO and hospital generics divisions, has led analysts to revise their outlook on the stock. Investors should monitor if the company can sustain this profit trajectory amid the typically lumpy nature of contract manufacturing orders.
Piramal Pharma reported a financial turnaround in the second quarter of the 2027 fiscal year, moving into profit after a period of losses. The company posted a net profit of Rs 50 million for the quarter, contrasting with market expectations of a loss of approximately Rs 684 million. This development marks a shift for the pharmaceutical firm, which has seen tepid results over the previous five quarters.
The improvement in performance is largely driven by the company’s two primary segments: the Contract Development and Manufacturing Organization (CDMO) business and the Complex Hospital Generics (CHG) division. These units have benefited from improved operational leverage, which helps the company convert revenue growth into better margins. By managing costs more efficiently while scaling these businesses, the company was able to surpass operating profit projections significantly.
Following these results, analysts at Motilal Oswal Financial Services have initiated coverage on the stock with a 'Buy' rating and a target price of Rs 270. To arrive at this valuation, the brokerage used a Sum-of-the-Parts (SOTP) analysis. This method involves valuing the CDMO, hospital generics, and India Consumer Healthcare segments individually and then combining them to determine a total equity value. This approach is commonly used for diversified companies to capture the different growth rates and profit profiles of separate business units.
While the Q2 performance is a positive signal, investors should note the nature of the CDMO business. Contract manufacturing often depends on large, specific orders from global clients, which can make revenue and profit patterns appear lumpy or irregular. The long-term success of the stock will likely depend on whether the company can maintain consistent execution across these global contracts without facing delays or cost increases.
Looking ahead, the market will focus on whether this profitability trend continues in the coming quarters. Key areas to monitor include the stability of operating margins, the ability to secure steady order flows in the CDMO segment, and the overall management of debt as the company seeks to scale its complex hospital generics portfolio. Investors should also watch for any commentary on demand trends in key international markets, which often dictate the pace of growth for domestic pharmaceutical companies with significant global operations.